Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Allergan Readies Cost Cuts As Restasis Generics Approach

Nov 02 2017

• By Mandy Jackson

Business decline

Related Content

With $36bn from Teva, what should Allergan buy next?

Jul 28 2015

982 California job cuts precede Actavis, Allergan merger

Dec 04 2014

Allergan Shifts Restasis Patents To Native American Tribe To Invoke Immunity From IPR

Sep 09 2017

Allergan Urgently Seeks FDA Guidance To Unblock Vraylar sNDA Review

Sep 25 2017

VENUS II Paves Way For Allergan's Ulipristal NDA In Uterine Fibroids

Jan 18 2017

Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma

Feb 04 2017

Related Companies

Allergan plc

Allergan plc

Allergan plc

Teva Pharmaceutical Industries Ltd.

Additional Topics

Business Strategies Commercial Companies Sales & Earnings BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.